What's behind Abbott's latest stock surge?

Traders Union
All News
Stocks
Abbott laboratories rises 2.40% today

Highlights

Abbott Laboratories reported second-quarter revenue up 13% to $12.59 billion and adjusted earnings per share of $1.31.
The company declared a quarterly dividend of $0.63 per share and agreed to a $385 million baby formula settlement with no admission of liability.
Shares of Abbott are encountering medium- and long-term resistance, with short-term momentum signals mixed and a five-day range of $100.23 to $104.13 forecast.

Growth offset by new launches and settlement resolution

Abbott Laboratories reported a 13% increase in second-quarter revenue to $12.59 billion and adjusted earnings per share of $1.31. The company also declared a quarterly dividend of $0.63 per share, translating to an annualized payout of $2.52 per share. Recent developments include the launch of Ensure Max Protein 3-in-1 Muscle Support and the release of SimpleScreen CRC, a blood-based colorectal cancer screening assay. In addition, Abbott agreed to pay nearly $385 million to settle claims related to manufacturing baby formula at an unsanitary facility, with the company stating the settlement was not an admission of fault or liability and that the associated criminal investigation has been closed.

Anton Kharitonov, expert at Traders Union, sees Abbott's recent advance as fragile and technically constrained. He notes that despite solid earnings and new product launches, the stock is capped under major moving averages and critical resistance levels, signaling persistent downside risk. Indicators such as MACD, CCI, and ADX align with ongoing selling pressure, while an overbought Stochastic RSI warns of potential exhaustion. News of a $385 million legal settlement further dampens sentiment, raising questions on risk and sustainability. "I view the current bounce as short-lived, with underlying signals and historical resistance presenting more headwinds than opportunities for buyers at these levels," Kharitonov states.

Viktoras Karapetjanc, expert at Traders Union, highlights strong second-quarter growth, robust revenue, and successful product launches as key demand drivers. He is confident that Abbott's fundamentals prove resilient, with ongoing innovation and closed legal matters supporting a constructive outlook. Despite current technical pressures, the company's dividend stability and aggressive product pipeline create a supportive macro backdrop for further growth. "With fundamentals intact and fresh innovation, I believe the bullish structure remains in place — investors should watch for upside follow-through above $103.34," Karapetjanc asserts.

Sholanke Dele, market strategist, questions the sustainability of Abbott's recent price jump. He warns that overall momentum readings remain weak, with sentiment impacted by the sizable legal settlement. The analyst notes that global macro uncertainty and seller dominance may persist. "Short-term gains are at risk of reversal as broader headwinds and lackluster momentum outweigh the recent positive news flow," says Dele.

Brief price strength contrasts with persistent negative momentum

Abbott is trading above its 20-day moving average ($100.75) but remains under both the 50-day ($106.17) and 200-day ($103.34) moving averages, reflecting short-term momentum but ongoing seller resistance over longer time frames. The Ichimoku Kijun ($103.56) presents further resistance, with overhead hurdles at $103.34 and support at $101.81. Although the broader alignment of the 50- versus 200-day averages continues to favor a long-term positive outlook, momentum readings stay negative. The MACD and ADX both point to a sell and indicate weak upward strength. The RSI is at 42.29, showing selling pressure, while the Stochastic RSI is sharply overbought at 99.33. The CCI remains negative, emphasizing continued downside risk. Positive Bull/Bear Power values signal intraday buyer dominance, but the indicator is flagged as oversold. Today's session saw a $2.40 or 2.4% intraday climb—opening with a $0.38 upside gap and near session highs—against a backdrop of 1.81% volatility. Although intraday strength is clear, most momentum indicators suggest caution and divergence from current price action.

Earlier, analysts noted that Abbott's technicals showed mixed momentum despite positive product developments, with traders cautious amid ongoing resistance. The latest results reinforce this outlook, as the stock's upward move remains constrained by persistent longer-term barriers, making a sustained break above $103.34 a key trigger to signal renewed directional strength.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.